Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD276 CAR-T for Advanced CD276+ Solid Tumors
NCT04691713Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of B7H3 CAR-T in solid tumor, sponsored by PersonGen BioTherapeutics. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
B7H3 CAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04691713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691713.